Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Retinoblastoma Gene01:20

The Retinoblastoma Gene

4.9K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.9K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

2.8K
2.8K
Ovarian Cycle01:27

Ovarian Cycle

5.1K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
5.1K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.6K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.6K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

5.9K
5.9K
Ovaries01:26

Ovaries

3.1K
The ovaries are roughly the size of almonds and measure approximately 2 to 3 centimeters in length. These paired structures are situated within the pelvic region and are anchored by the mesovarium—a peritoneal extension that also connects them to the wider structure of the broad ligament. The support system extends to the suspensory ligament, housing blood and lymphatic vessels. In addition, the ovarian ligament tethers the ovaries to the uterus.
On the ovarian surface, a layer of...
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Maintenance of PARP Inhibitor Rechallenge plus Bevacizumab in Patients with Platinum-Sensitive, Recurrent Ovarian Cancer Previously Treated with a PARP Inhibitor.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Reply to Letter to the Editor "Long-term follow-up of PAOLA-1 and the evolving landscape of post-PARP treatment strategies in ovarian cancer" by Arenhardt and Nogueira-Rodrigues.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Predictive value of BRCA1/RAD51C methylation in HGSOC - An ancillary study of the PAOLA-1/ENGOT-ov25 phase 3 trial.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Dostarlimab and niraparib in primary advanced ovarian cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

HR-SC-an academic-developed machine learning framework to classify HRD-positive ovarian cancer patients and predict sensitivity to olaparib.

ESMO open·2025
Same author

Exposure-response relationship of niraparib in maintenance therapy for recurrent ovarian cancer: ancillary analysis of the French GINECO-NiQoLe study.

ESMO open·2025
Same journal

The ethical obligation to use positive trial results.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Lorlatinib: The Crown Jewel of ALK Inhibitors.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

TROP2-Directed Antibody Drug Conjugates: New First-Line Treatment for All Patients with Advanced Triple-Negative Breast Cancer?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

When artificial intelligence learns to abstain: towards clinically responsible diagnostic support in liver pathology.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

PRMT5 inhibitors in MTAP loss NSCLC with actionable genomic alterations: a new kid on the block?

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same journal

Refining decision making in hormone receptor-positive early-stage breast cancer: moving from static to dynamic.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
See all related articles

Related Experiment Video

Updated: Mar 21, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Recurrent ovarian cancer.

E Pujade-Lauraine1, P Combe2

  • 1Université Paris Descartes, APHP, Hôpital Hôtel-Dieu, Paris epujade@arcagy.org.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|May 4, 2016
PubMed
Summary
This summary is machine-generated.

Advanced ovarian cancer recurrence is common, but new targeted therapies like anti-angiogenic and anti-PARP agents are improving survival. Future research will focus on personalized, multi-factorial approaches beyond platinum-free intervals.

More Related Videos

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K

Related Experiment Videos

Last Updated: Mar 21, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K
Quantitation of Intra-peritoneal Ovarian Cancer Metastasis
10:58

Quantitation of Intra-peritoneal Ovarian Cancer Metastasis

Published on: July 18, 2016

11.6K
Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction
05:42

Author Spotlight: Advanced Ex Vivo Model for Investigating Cancer-Adipose Microenvironment Interaction

Published on: January 26, 2024

3.3K

Area of Science:

  • Oncology
  • Clinical Research
  • Pharmacology

Background:

  • Advanced ovarian cancer frequently recurs, necessitating improved management strategies.
  • Recent therapeutic advancements have shifted focus from traditional chemotherapy to targeted therapies.
  • Targeted agents, including anti-angiogenic and anti-PARP drugs, are increasingly important in managing relapsed disease.

Purpose of the Study:

  • To review the evolving landscape of ovarian cancer treatment, focusing on targeted therapies.
  • To highlight the limitations of current prognostic criteria like platinum-free interval.
  • To identify emerging areas for clinical research in personalized ovarian cancer management.

Main Methods:

  • Literature review of recent advancements in ovarian cancer therapy.
  • Analysis of the shift from chemotherapy to targeted agents.
  • Discussion of future research directions in personalized medicine.

Main Results:

  • Targeted therapies, particularly anti-angiogenic and anti-PARP agents, have significantly improved survival in relapsing ovarian cancer.
  • The platinum-free interval may be superseded by multi-factorial approaches for prognosis and prediction.
  • Personalized therapy necessitates research into areas like multi-line relapse and frail patient management.

Conclusions:

  • The management of advanced ovarian cancer is increasingly personalized, moving beyond chemotherapy.
  • Future research should address the needs of patients with multi-line relapse and frail individuals.
  • A multi-factorial approach is essential for future prognostic and predictive criteria in ovarian cancer.